IBI310 + SINTILIMAB + SURUFATINIB

1 treatment and condition followed through the public trial records. Not medical advice. How a status is set

Treatments and conditions

IBI310 + SINTILIMAB + SURUFATINIB
Treatment and conditionWhere it standsTrials
IBI310 + SINTILIMAB + SURUFATINIB for neuroendocrine tumorsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1